Stock & Company Details
Insmed Inc $INSM
Price:
N/A
N/A
218M
$22B
52 Week High:
N/A
10 Day Average Volume:
N/A
-24.48
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
INSM technical indicators
Latest Insmed Inc (INSM) indicator readings as of 2026-10-09.
INSM's 14-day RSI is 29.7, in oversold territory. At $100.60 it is trading 23.2% below its 200-day moving average of $131.06, and below its 50-day average of $119.65. Price sits near the lower Bollinger Band ($98.40 to $130.64). ADX reads 34.5, indicating a trending market.
INSM backtested strategy results
How 4 rule-based strategies performed on Insmed Inc (INSM) over recent history, last backtested 2026-09-03. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +208.5% | 56% | 9 | -36.3% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | +36.1% | 21% | 28 | -59.4% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +63.2% | 39% | 28 | -37.6% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +43.1% | 74% | 23 | -30.4% |
Overview
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Finance Bot
Ask your questions
Start by typing a question below.
